The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial

MLA

Otto Dietze, et al. “The Genomic Expression Test EndoPredict Is a Prognostic Tool for Identifying Risk of Local Recurrence in Postmenopausal Endocrine Receptor-Positive, Her2neu-Negative Breast Cancer Patients Randomised within the Prospective ABCSG 8 Trial.” British Journal of Cancer, vol. 112, no. 8, July 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e83be9b92fb22456c84a7bdaa26b2036&authtype=sso&custid=ns315887.

APA

Otto Dietze, Sigurd Lax, Michael Gnant, Ralf Kronenwett, Richard Greil, Florian Fitzal, Margarethe Rudas, Martin Filipits, W Herz, Rupert Bartsch, Hellmut Samonigg, & P. Dubsky. (2014). The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. British Journal of Cancer, 112(8).

Chicago

Otto Dietze, Sigurd Lax, Michael Gnant, Ralf Kronenwett, Richard Greil, Florian Fitzal, Margarethe Rudas, et al. 2014. “The Genomic Expression Test EndoPredict Is a Prognostic Tool for Identifying Risk of Local Recurrence in Postmenopausal Endocrine Receptor-Positive, Her2neu-Negative Breast Cancer Patients Randomised within the Prospective ABCSG 8 Trial.” British Journal of Cancer 112 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e83be9b92fb22456c84a7bdaa26b2036&authtype=sso&custid=ns315887.